Industry-Sponsored Research Week
University-Industry Engagement Advisor

University of Montreal cancer research institute enters research collaboration with AbbVie

By David Schwartz
Published: June 12th, 2018

The University of Montreal’s Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) has entered into a research collaboration with biopharma company AbbVie to identify Tumor-Specific Neoantigens (TSNAs) based on a novel proprietary platform developed by Institute researchers Claude Perreault and Pierre Thibault.

The agreement calls for AbbVie to fund research aimed at identifying TSNA in a specific cancer indication, and the company gets an option to secure an exclusive worldwide license on the intellectual property arising from the collaboration.

“We are very pleased to have been able to successfully conclude an agreement with AbbVie around the identification of TSNA[s] that are of mutual interest to both AbbVie and to IRICoR,” said Steven Klein, the Insitute’s VP for business development. “Having a partner such as AbbVie validates the novel approach that Drs. Perreault and Thibault have developed to identify TSNA across multiple tumor types, and demonstrates the value of IRICoR in initially funding this unique platform.”

Thomas Hudson, AbbVie’s VP  and head of oncology discovery and early development, said the company “is truly excited about this partnership because it provides a real opportunity to identify new antigens that are produced in cancer cells, which the immune system can recognize. Drs. Perreault’s and Thibault’s work consists of developing technologies to identify these specific proteins at the surface of cancer cells, and their approach is quite novel. It’s an area of immuno-oncology we are eager to investigate in order to accelerate and discover new therapies.”

Added Stéphane Lassignardie, general manager of AbbVie Canada: “Drs. Perreault’s and Thibault’s research will undoubtedly have a remarkable impact on how we treat cancer. Ultimately, AbbVie looks for innovative partnerships and partners who are pushing the boundaries of science in order to tackle the toughest challenges in oncology.”

Source: Cision

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment